NANO.OL - Nordic Nanovector ASA

Oslo - Oslo Delayed Price. Currency in NOK
20.88
+0.30 (+1.46%)
At close: 4:25PM CET
Stock chart is not supported by your current browser
Previous Close20.58
Open21.38
Bid20.82 x 100000
Ask20.92 x 10000
Day's Range20.46 - 21.38
52 Week Range19.75 - 89.47
Volume470,803
Avg. Volume563,470
Market Cap1.381B
Beta (3Y Monthly)-0.06
PE Ratio (TTM)N/A
EPS (TTM)-7.11
Earnings DateNov 19, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est112.50
  • PR Newswire

    Nordic Nanovector to Participate in Four Upcoming Investor Conferences

    Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. This press release contains certain forward-looking statements.

  • PR Newswire

    Nordic Nanovector ASA: Invitation to Third Quarter 2019 Results Presentation and Webcast

    OSLO, Norway , Nov. 13, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the third quarter 2019 on Tuesday, 19 November 2019. A presentation by Nordic ...

  • PR Newswire

    Nordic Nanovector ASA: Mandatory Notification of Trade - Primary Insider

    OSLO, Norway , Oct. 24, 2019 /PRNewswire/ -- Tone Kvåle, CFO, has today, 24 October 2019 , purchased 5,000 shares in Nordic Nanovector ASA (the "Company") at an average share price of NOK 19.96 ...

  • PR Newswire

    Nordic Nanovector ASA - Resolution not to Proceed With a Repair Offering

    OSLO, Norway, Oct. 24, 2019 /PRNewswire/ -- Reference is made to the stock exchange announcement on 18 October 2019 where Nordic Nanovector ASA (NANO.OL) (the "Company") announced the successful completion of a private placement raising gross proceeds of NOK 242,525,624 (the "Private Placement") and that the board of directors would consider to carry out a repair offering of up to 2,204,778 new shares (the "Repair Offering"). The Company has decided not to proceed with the Repair Offering. Since announcement of completion of the Private Placement on 18 October 2019, the Company's shares have traded on the Oslo Stock Exchange, with sufficient trading volume, at prices close to or below the subscription price in the Private Placement of NOK 22.

  • PR Newswire

    Nordic Nanovector ASA - Tranche 1 Share Capital Increase Registered

    OSLO, Norway, Oct. 23, 2019 /PRNewswire/ --  Reference is made to the stock exchange announcement on 18 October 2019 regarding the successful completion of Nordic Nanovector ASA's (NANO.OL) (the "Company") private placement of new shares (the "Private Placement"). The Private Placement is divided into two tranches, as further explained in the stock exchange announcement on 18 October 2019. The share capital increase pertaining to the 5,511,946 new shares, each with a nominal value of NOK 0.20, to be issued in tranche 1 of the Private Placement (the "Tranche 1 Shares") has been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 23 October 2019, and the Company's share capital has been increased with NOK 1,102,389.20 through the issuance of the Tranche 1 Shares.

  • PR Newswire

    Nordic Nanovector Launches a Private Placement of New Shares

    Nordic Nanovector ASA (NANO.OL) ("Nordic Nanovector" or the "Company"), a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics, announces the launch of a private placement of new shares (the "Offer Shares") representing up to approximately 20% of the outstanding share capital of the Company at this date (the "Private Placement"). DNB Markets and Jefferies International Limited are acting as Joint Global Coordinators and joint bookrunners (the "Joint Global Coordinators"), and ABG Sundal Collier ASA is acting as joint bookrunner (together with the Joint Global Coordinators, the "Managers") in connection with the Private Placement.

  • PR Newswire

    Nordic Nanovector ASA - Tranche 2 Share Capital Increase Registered

    OSLO, Norway, Oct. 21, 2019 /PRNewswire/ -- Reference is made to the stock exchange announcement on 18 October 2019 regarding the successful completion of Nordic Nanovector ASA's (NANO.OL) (the "Company") private placement of new shares (the "Private Placement") The Private Placement is divided into two tranches, as further explained in the stock exchange announcement on 18 October 2019. The share capital increase pertaining to the 5,511,946 new shares, each with a nominal value of NOK 0.20, to be issued in tranche 2 (the "Tranche 2 Shares") has been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 21 October 2019, and the Company's share capital has been increased with NOK 1,102,389.20 through the issuance of the Tranche 2 Shares.

  • PR Newswire

    Nordic Nanovector ASA - Key Information Regarding Potential Repair Offering

    OSLO, Norway , Oct. 18, 2019 /PRNewswire/ --  Reference is made to the announcement by Nordic Nanovector ASA (OSE: NANO) ("Nordic Nanovector" or the "Company") on 18 October 2019 concerning ...

  • PR Newswire

    Nordic Nanovector - Private Placement Successfully Completed

    OSLO, Norway, Oct. 18, 2019 /PRNewswire/ -- Reference is made to the stock exchange release from Nordic Nanovector ASA (NANO.OL) ("Nordic Nanovector" or the "Company"), a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics, published on 17 October 2019 regarding the contemplated private placement of new shares in the Company. The Company announces today that it has raised NOK 242,525,624 (equivalent to approximately USD 26.4 million) in gross proceeds through a private placement (the "Private Placement") of 11,023,892 new shares (the "New Shares"). The Private Placement was completed at a subscription price of NOK 22.00 per share, which was determined through an accelerated book-building process.

  • PR Newswire

    Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)

    OSLO, Norway , Oct. 9, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators at Orano Med will present data and analyses from preclinical studies with ...

  • PR Newswire

    Nordic Nanovector Signs Global Clinical and Commercial Agreement With ITM for the Supply of No-carrier-added Lutetium-177

    OSLO, Norway, Oct. 7, 2019 /PRNewswire/ -- Nordic Nanovector ASA (NANO.OL) announces that it has signed a long-term global supply agreement with a subsidiary of ITM Isotopen Technologien München AG (ITM), Isotope Technologies Garching GmbH (ITG) to ensure the supply of high quality, no-carrier-added (n.c.a.) Lutetium-177, a key component of Betalutin® (177Lu-lilotomab-satetraxetan) for R&D, clinical and commercial uses. ITM, a biotechnology and radiopharmaceutical group of companies and world-leader in the development and production of radiopharmaceuticals and radionuclides for the targeted treatment of cancers as well as for diagnostics, has been supplying n.c.a. Marco Renoldi, Chief Operating Officer at Nordic Nanovector, said: "We are pleased to extend our collaboration with a long-time and reliable partner such as ITM.

  • PR Newswire

    Nordic Nanovector Appoints Dr Gabriele Elbl as Vice President Global Regulatory Affairs

    OSLO, Norway, Oct. 1, 2019 /PRNewswire/ -- Nordic Nanovector ASA (NANO.OL) announces the appointment of Dr Gabriele Elbl as Vice President Global Regulatory Affairs. Dr Elbl is a pharmacist with more than 20 years' experience working in small and large pharmaceutical companies and at the European Medicines Agency (EMA). Dr Elbl will join Nordic Nanovector on 1 November 2019 from Mundipharma EDO, where she was Global Head of Regulatory Affairs Oncology.

  • PR Newswire

    Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options

    OSLO, Norway, Sept. 19, 2019 /PRNewswire/ -- One former employee and a participant in the Company's previous share option program, not being a primary insider, has exercised a total number of 5,775 options through exercise of a corresponding number of free-standing warrants. Each free-standing warrant gives the right to receive one share in the Company. The share capital increase related to the exercise of the options has been duly registered in the Norwegian Register of Business Enterprises.